LRRK2相关帕金森病的进展特征:前瞻性纵向研究
该前瞻性纵向研究纳入545例德系犹太人帕金森病患者,其中144例携带LRRK2 G2019S突变,评估LRRK2突变对帕金森病进展的影响。结果显示LRRK2突变患者统一帕金森病评定量表III部分运动评分年变化率较无突变者更慢,差异有统计学意义;认知功能变化率组间差异未达统计学意义。
要点
- LRRK2 G2019S突变帕金森病患者运动症状进展较无突变者慢。
- LRRK2突变患者认知功能下降速率与无突变者无显著差异。
- 该研究支持LRRK2相关帕金森病进展较慢的观点,对临床试验设计有参考价值。
核心结论
- LRRK2 G2019S相关帕金森病患者运动功能下降速度较无突变者慢。
研究设计与样本
- 前瞻性纵向研究,纳入545例德系犹太人帕金森病患者,其中144例(26.4%)携带LRRK2 G2019S突变。
- 2009年7月21日至2016年9月30日于3个中心进行,所有患者接受1至4次研究访视。
- 排除GBA突变患者,采用线性混合效应模型分析运动评分变化。
临床怎么用
- 对于LRRK2 G2019S突变帕金森病患者,运动症状进展可能较慢,临床评估和咨询时可参考此信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Few prospective longitudinal studies have evaluated the progression of Parkinson disease (PD) in patients with the leucine-rich repeat kinase 2 (LRRK2 [OMIM 609007]) mutation. Knowledge about such progression will aid clinical trials. OBJECTIVE: To determine whether the longitudinal course of PD in patients with the LRRK2 mutation differs from the longitudinal course of PD in patients without the mutation. DESIGN, SETTING, AND PARTICIPANTS: A prospective comprehensive assessment of a large cohort of patients from 3 sites with LRRK2 PD or with nonmutation PD was conducted from July 21, 2009, to September 30, 2016. All patients of Ashkenazi Jewish ancestry with PD were approached at each site; approximately 80% agreed to an initial visit. A total of 545 patients of Ashkenazi Jewish descent with PD who had 1 to 4 study visits were evaluated. A total of 144 patients (26.4%) had the LRRK2 G2019S mutation. Patients with GBA (OMIM 606463) mutations were excluded from the analysis. MAIN OUTCOMES AND MEASURES: Linear mixed-effects models for longitudinal motor scores were used to examine the association of LRRK2 mutation status with the rate of change in Unified Parkinson's Disease Rating Scale III scores using disease duration as the time scale, adjusting for sex, site, age, disease duration, cognitive score, and levodopa-equivalent dose at baseline. Mixed-effects models were used to assess change in cognition, as measured by Montreal Cognitive Assessment scores. RESULTS: Among the 545 participants, 233 were women, 312 were men, and the mean (SD) age was 68.2 (9.1) years for participants with the LRRK2 mutation and 67.8 (10.7) years for those without it. Seventy-two of 144 participants with the LRRK2 mutation and 161 of 401 participants with no mutation were women. The estimate (SE) of the rate of change in the Unified Parkinson's Disease Rating Scale III motor score per year among those with the LRRK2 mutation (0.689 [0.192] points per year) was less than among those without the mutation (1.056 [0.187] points per year; difference, -0.367 [0.149] points per year; P = .02). The estimate (SE) of the difference in the rate of change of the Montreal Cognitive Assessment score between those with the LRRK2 mutation (-0.096 [0.090] points per year) and those without the mutation (-0.192 [0.102] points per year) did not reach statistical significance (difference, 0.097 [0.055] points per year; P = .08). CONCLUSIONS AND RELEVANCE: Prospective longitudinal follow-up of patients with PD with or without the LRRK2 G2019S mutation supports data from a cross-sectional study and demonstrates a slower decline in motor Unified Parkinson's Disease Rating Scale scores among those with LRRK2 G2019S-associated PD.
引用
- Saunders-Pullman R, Mirelman A, Alcalay RN, et al. Progression in the LRRK2-Asssociated Parkinson Disease Population. JAMA Neurol. 2018. PMID: 29309488. doi:10.1001/jamaneurol.2017.4019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。